259183-86-3Relevant academic research and scientific papers
NOVEL COMPOUND, PREPARATION METHOD THEREOF, AND USE THEREOF
-
Paragraph 452; 458-460, (2021/07/24)
The present invention relates to a method for preparing a biomaterial having selectively functionalized tyrosine, a biomaterial having selectively functionalized tyrosine, and a pharmaceutical composition containing the same as an active ingredient. The method for preparing a biomaterial to which a compound represented by formula 2 is coupled, of the present invention, allows the compound represented by formula 2 to be selectively coupled, in a high yield in a biomaterial, to tyrosine, which is present on the surface of an aqueous solution such that the coupling thereof to amino acids other than tyrosine does not occur and, when only one tyrosine is present, heterogeneous mixtures are not present and the inherent activity of the biomaterial is maintained, and thus the compound can be effectively used as a pharmaceutical composition containing a biomaterial drug as an active ingredient. In addition, the method can selectively functionalize tyrosine, and thus can be effectively used for tyrosine functionalization in a biomaterial.
Histone deacetylase inhibitor, and preparation method and use thereof
-
Paragraph 0129; 0131-0133, (2019/10/04)
The present invention discloses a histone deacetylase inhibitor, and concretely discloses a compound represented by formula I, and a stereoisomer thereof. The novel compound of the formula I has a good deacetylase inhibition activity, and provides a new m
Prodrugs of proton pump inhibitors
-
, (2008/06/13)
Prodrugs of the pyridyl methyl sulfinyl benzimidazole type proton pump inhibitor drugs have a hydrolyzable arylsulfonyl or heteroarylsulfonyl group attached to the benzimidazole nitrogen. The prodrugs of the invention hydrolyze under physiological conditions to provide the proton pump inhibitors with a half life measurable in hours, and are capable of providing sustained plasma concentrations of the proton pump inhibitor drugs for longer time than presently used drugs. The generation of the proton pump inhibitor drugs from the prodrugs of the invention under physiological conditions allows for more effective treatment of several diseases and conditions caused by gastric acid secretion.
